Enesi Pharma has entered into an R&D agreement with Australian biotech Sementis aimed to needle-free solid dose vaccines for peanut allergy as well as Zika infection.
The collaboration is focused on the development and evaluation of solid dose versions of Sementis’ lead peanut hypoallergy vaccine and its single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma’s ImplaVax technology.
ImplaVax is a proprietary needle-free solid dose implant and device technology for subcutaneous vaccination.
Data to date demonstrate that ImplaVax-enabled vaccines can deliver superior immune responses compared to standard injection protocols among other benefits such as safety, ease of use, reliability and stability.
Sementis’ investigational peanut hypoallergy vaccine – based on its SCV vector platform – has completed proof-of-concept studies, providing compelling evidence that it offers the possibility of a permanent cure for peanut allergy.
It is estimated that over seven million individuals suffer with serious allergy to peanut, including many children, in the major markets of the US, Europe and Japan. This represents an estimated cost to healthcare systems in the tens of billions of US dollars annually.
An ImplaVax-enabled vaccine could provide a simple and effective means to address peanut allergy on a large scale, particularly for younger sufferers who may have an aversion to needles and traditional injections.
Sementis’ single vectored vaccine for chikungunya/Zika virus infection is equally promising with extensive proof-of-concept studies in mice demonstrating the effectiveness of the vaccine in protecting against Zika and chikungunya from a single vaccination shot.
An ImplaVax-enabled product using the Sementis SCV chikungunya/Zika vaccine offers the potential to provide long-lasting immunity and retain potency across a wide range of storage conditions for prolonged periods.
Enesi Pharma will formulate solid dose implants based on SCV vaccine provided by Sementis, who will undertake safety and immunogenicity testing, and preclinical development.